Thermo Fisher Scientific and Agios Pharmaceuticals have entered into an agreement under which a next-generation sequencing-based companion diagnostic will be developed and commercialized for Agios' investigational cancer drug ivosidenib. The companion diagnostic is intended for identifying IDH1 mutations using Thermo Fisher's Ion AmpliSeq technology, Ion PGM Dx system and Oncomine portfolio; the companies did not disclose additional terms of the deal.
Thermo Fisher enters CDx development partnership with Agios
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.